Research Article

Eucommia ulmoides Oliv. (Du-Zhong) Lignans Inhibit Angiotensin II-Stimulated Proliferation by Affecting P21, P27, and Bax Expression in Rat Mesangial Cells

Xian Jing, 1,2,3 Wei-Hua Huang, 1,2 Yong-Jun Tang, 1,2 Ya-Qin Wang, 1,2 Hui Li, 1,2 Ying-Ying Tian, 1,2 Yao Chen, 1,2 Hong-Hao Zhou, 1,2 and Dong-Sheng Ouyang 1,2

1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
2Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
3Yihe Hospital of Zhengzhou, Zhengzhou 450047, China

Correspondence should be addressed to Dong-Sheng Ouyang; ouyangyj@163.com

Received 31 March 2015; Revised 17 May 2015; Accepted 21 May 2015

Academic Editor: Darren R. Williams

Copyright © 2015 Xian Jing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cortex Eucommiae (Du-zhong) is the dried bark of the Eucommia ulmoides Oliv. The natural products identified from Du-zhong include lignans, iridoids, flavonoids, polysaccharides, terpenes, and proteins [1]. Lignans, the main bioactive components, were protective against hypertensive renal injury in spontaneous hypertensive rats in our previous study [2]. Moreover, Eucommia lignans also diminished aldose reductase (AR) overexpression in the kidney [2]. However, the pathological mechanism underlying the protective effects of Eucommia lignans remains unknown. Cellular proliferation was reported to contribute to important pathological changes in hypertensive renal injuries, and increased angiotensin II (Ang II) expression was reported to be essential for target-organ damage during hypertension. Ang II is the main effective peptide in the renin-angiotensin system and is considered to be a key mediator in the development of hypertensive nephropathy [3]. Ang II regulates the proliferation of RMCs and increases the formation of the extracellular matrix primarily through the induction of glomerular hypertension and nonhemodynamic effects, including the production of reactive oxygen species and the upregulation of AR overexpression in the kidney [2]. However, the pathological mechanism underlying the protective effects of Eucommia lignans remains unknown. Cellular proliferation was reported to contribute to important pathological changes in hypertensive renal injuries, and increased angiotensin II (Ang II) expression was reported to be essential for target-organ damage during hypertension. Ang II is the main effective peptide in the renin-angiotensin system and is considered to be a key mediator in the development of hypertensive nephropathy [3]. Ang II regulates the proliferation of RMCs and increases the formation of the extracellular matrix primarily through the induction of glomerular hypertension and nonhemodynamic effects, including the production of reactive oxygen species and the upregulation of AR overexpression in the kidney [2]. However, the pathological mechanism underlying the protective effects of Eucommia lignans remains unknown. Cellular proliferation was reported to contribute to important pathological changes in hypertensive renal injuries, and increased angiotensin II (Ang II) expression was reported to be essential for target-organ damage during hypertension. Ang II is the main effective peptide in the renin-angiotensin system and is considered to be a key mediator in the development of hypertensive nephropathy [3]. Ang II regulates the proliferation of RMCs and increases the formation of the extracellular matrix primarily through the induction of glomerular hypertension and nonhemodynamic effects, including the production of reactive oxygen species and the upregulation of

1. Introduction

Cortex Eucommiae (Du-zhong) is the dried bark of the Eucommia ulmoides Oliv. (family: Eucommiaceae) and is one of the most popular tonic herbs in Asia. The natural products identified from Du-zhong include lignans, iridoids, flavonoids, polysaccharides, terpenes, and proteins [1]. Lignans, the main bioactive components, were protective against hypertensive renal injury in spontaneous hypertensive rats in our previous study [2]. Further study showed that Eucommia lignans decreased both N-acetyl-β-D-glucosaminidase enzyme activity and the ratio of albumin to urinary creatinine in spontaneous hypertensive rats. Moreover, Eucommia lignans also diminished aldose reductase (AR) overexpression in the kidney [2]. However, the pathological mechanism underlying the protective effects of Eucommia lignans remains unknown. Cellular proliferation was reported to contribute to important pathological changes in hypertensive renal injuries, and increased angiotensin II (Ang II) expression was reported to be essential for target-organ damage during hypertension. Ang II is the main effective peptide in the renin-angiotensin system and is considered to be a key mediator in the development of hypertensive nephropathy [3]. Ang II regulates the proliferation of RMCs and increases the formation of the extracellular matrix primarily through the induction of glomerular hypertension and nonhemodynamic effects, including the production of reactive oxygen species and the upregulation of
fibrotic growth factors. Our preliminary results showed that *Eucommia* lignans had inhibitory effects on Ang II-induced proliferation of rat mesangial cells. In the present study, we investigated the effects of *Eucommia ulmoides* on Ang II-induced proliferation and apoptosis of rat mesangial cells.

**2. Materials and Methods**

**2.1. Materials and Reagents.** Human angiotensin II was purchased from Sigma-Aldrich (St. Louis, MO, USA). The lignan content in *Eucommia* lignans was determined to be 71% by spectrophotometry on a Beckman Coulter DU 640 spectrophotometer (Beckman Coulter, Inc., USA) at 277 nm; the lignans were extracted from *Eucommia ulmoides* Oliv. bark in our own laboratory using a previously described method [2].

The primers for P21, P27, Bax, Bcl-2, and AR were purchased from Invitrogen (Carlsbad, CA, USA). Antibodies against P21, P27, Bax, Bcl-2, and AR for western blotting were supplied by Abcam (Cambridge, England) and Santa Cruz (CA, USA). The Cell Titer 96 Aqueous One Solution Proliferation Assay for the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method was purchased from Promega (Madison, WI, USA). The RT-qPCR kits with Platinum SYBR Green qPCR Super Mix-UDG and flow cytometry were purchased from Invitrogen (Carlsbad, CA, USA). Epalrestat was obtained commercially from Yuancheng Pharmaceutical Co., Ltd. (Hubei, China). The MTT One-Step Cell Proliferation Test Kit and Annexin V-FITC Apoptosis Assay Kit were purchased from Promega Corporation and Bibo Biological Technology Co., Ltd. (Nanjing, China), respectively.

**2.2. Cell Culture.** Rat mesangial cells (RMCs, China Type Culture Collection, Wuhan, China) were maintained in a humidified incubator with 5% CO₂/95% air at 37°C and propagated in RPMI-1640 medium supplemented with 10% newborn calf serum (NCS). Cell lines were passaged every three days after treatment with trypsin-ethylenediaminetetraacetic acid. Cells were used for experiments from passages 5–15.

**2.3. MTT Assay.** RMCs viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide. Briefly, cells were plated in 96-well tissue culture plates at a density of 1 x 10⁵ cells/mL. The cells were washed twice with phosphate-buffered saline when they reached 60% confluence and incubated for 24, 48, or 72 h in serum-deprived medium. During this final incubation, RMCs were treated with one of the following regimens for 24, 36, or 48 hours: control group (cultured RMCs coincubated with 1% NCS medium), Ang II group (10⁻⁸ mol/L Ang II), epalrestat group (10⁻⁸ mol/L Ang II + 20 μmol/L of the AR inhibitor epalrestat; positive control group), low concentration lignan group (10⁻⁸ mol/L Ang II + 20 mg/L lignans), middle concentration lignan group (10⁻⁸ mol/L Ang II + 40 mg/L lignans), and high concentration lignan group (10⁻⁸ mol/L Ang II + 80 mg/L lignans). Each concentration was tested in at least six replicates. Subsequently, 20 μL of the Cell Titer 96 Aqueous

**2.4. Reverse Transcription Real-Time Quantitative PCR (RT-qPCR) Assay.** RMCs were seeded into six-well plates at a density of 1 x 10⁵ cells per well. The 6 groups [control group (cultured RMCs coincubated with 1% NCS medium), Ang II group (10⁻⁸ mol/L Ang II), epalrestat group (10⁻⁸ mol/L Ang II + 20 μmol/L epalrestat), and the lignan groups (10⁻⁸ mol/L Ang II + 20, 40, or 80 mg/L lignans)] were cultured in RPMI-1640 medium containing 1% NCS for 48 h. The total RNA from the RMCs was extracted using the TRIzol reagent (Invitrogen, CA, USA), and the RNA concentration was determined by spectrophotometry at 260 and 280 nm. The cDNA was reverse-transcribed from the total RNA and treated with the real-time RT-PCR kits. The gene-specific primers are listed in Table I. The data were quantitatively analyzed with the Stratagene Mx3000p Real-Time PCR machine (Santa Clara, CA, USA). The beta-actin (β-actin) and glyceraldehyde phosphate dehydrogenase (GAPDH) genes were used as internal controls.

**2.5. Western Blot Assay.** Total protein was extracted from RMCs with radioimmunoprecipitation assay lysis buffer after 48 h of culture under the conditions described above; the protein concentration was determined with a Bicinchoninic Acid Assay Kit (Sigma-Aldrich, USA). Samples containing 40 μg of total protein were separated on a 10% sodium dodecyl sulfate polyacrylamide gel and transferred onto a polyvinylidene fluoride membrane. The membrane was blocked with 5% skim milk solution in Tris-buffered saline supplemented with 0.1% Tween-20 overnight. Subsequently, one of the primary antibodies (rabbit polyclonal antibody to P21, goat polyclonal antibody to P27, rabbit polyclonal antibody to Bax, mouse monoclonal [IST-9] antibody to Bcl-2, goat polyclonal antibody to AR, or rabbit polyclonal antibody to GAPDH) was added for hybridization. Then,

---

**Table I: Information on the primers used for real-time PCR.**

| Genes | Primers sequence |
|-------|------------------|
| P21   | F: 5'-TCATGGCCGACCTGTCCAGCAG-3' |
|       | R: 5'-CCCCAGCGCCGCTCCGCTCC-3'|
| P27   | F: 5'-GAGCTTGGATGTCAGCCGAGGAG-3'|
|       | R: 5'-CCGTCGCTTCGAGTGGCTCC-3'|
| Bax   | F: 5'-GAAGATGCGTCCAGGCTTCTC-3'|
|       | R: 5'-TCCCGGGTCCTGGCAGATTC-3'|
| Bcl-2 | F: 5'-ATGTGGTGAGGGAGGCTCA-3'|
|       | R: 5'-GTCGCAATGCGCCGTCAG-3'|
| AR    | F: 5'-TCCAGAGATCAAGGAAATGG-3'|
|       | R: 5'-ACAACAGGAACTGGGAGGTG-3'|
| β-actin | F: 5'-CATTTGCACCAACTGGGACAGTA-3' |
|       | R: 5'-GGATGCGCTACGTACATGGCGT-3' |
the blots were incubated with the specific secondary antibody after the membranes were washed with TBST three times. Finally, the protein bands were visualized using the Enhanced Chemiluminescence Western Blotting Detection System (Millipore, USA), and β-actin and GAPDH were selected as the internal standards for data normalization.

2.6. Cell Cycle and Apoptosis Analysis. Rat mesangial cells were treated with one of the following regimens for 24, 36, or 48 h: (1) control; (2) Ang II group (10⁻⁸ mol/L Ang II); (3) epalrestat group (10⁻⁸ mol/L Ang II + 20 μmol/L epalrestat); and (4) Ang II + different concentrations of lignans (20, 40, or 80 mg/L). Each concentration was tested with at least three replicates. Briefly, 4 × 10⁴ cells were harvested by centrifugation, washed with phosphate-buffered saline, fixed with 70% (v/v) cold aqueous ethanol, and stored overnight at −20°C. The fixed cells were washed with phosphate-buffered saline and incubated with propidium iodide containing 0.05% RNase. The samples were incubated at 4°C in the dark and analyzed by flow cytometry. The percentage of cells in the S, G1, G2, and M phases was assessed by Diva software (Data-Interpolating Variational Analysis). Also apoptosis rate (%) = number of apoptotic cells/total cells × 100%

2.7. Enzyme Activity Assays. After the cells were cultured in 6-well plates for 48 h, nonadherent cells were extracted into a 1.5 mL EP tube. To recover the adherent cells, 500 μL of trypsin (0.25%) was added to the 6-well plates and incubated for approximately 30 s; then, the nonadherent cells and adherent cells were mixed and centrifuged at 1000 r/min for 10 min and washed twice with PBS. A total of 200 μL of potassium phosphate buffer (pH 6.0) was added to the 1.5 mL EP tubes to resuspend the precipitates, and then the precipitates were shaken in a humidified incubator at 4°C for 10 min. The tube contents were mixed by flicking with a finger to ensure perfect cell lysis. No obvious cell precipitation was observed after full lysis. Then, the cells were centrifuged at 12,000 r/min for 40 min, and the supernatant was used to assess the enzyme activity. Each sample was incubated in triplicate on ice. The reaction system (200 μL) consisted of 5 μL of supernatant, 135 mM PBS, 100 mM ammonium sulfate, 0.04 mM DL-glyceraldehyde, and 150 μM NADPH. The reaction was kept in a humidified incubator at 37°C for 4 min after the addition of DL-glyceraldehyde. The absorbency was recorded using an ultraviolet spectrophotometer (Xianke Instrument Co., Ltd., Shanghai, China).

2.8. Statistical Analysis. Data were expressed as the mean ± SD. The differences between groups were analyzed by one-way analysis of variance and the Student-Newman-Keuls t-test with the SPSS 17.0 software. Statistical significance was defined as P < 0.05.

3. Results

3.1. Effects of Eucommia Lignans on Ang II-Induced Changes in the RMCs Cell Cycle. The cell cycle distribution of RMCs treated with Ang II showed a significant reduction in the ratio of cells in G1 phase (P < 0.05) and an elevation in the ratio of cells in S phase. These effects were alleviated by Eucommia lignans (P < 0.01) (Table 2) in a concentration-dependent manner.

3.2. Effects of Eucommia Lignans on Ang II-Induced P21 and P27 Expression in Rat Mesangial Cells. The RT-qPCR assay showed that the P21 and P27 mRNA expression levels in the Ang II group were weaker than the control (P < 0.01) (Figure 1). Western blot analyses demonstrated that P21 and P27 protein expression levels in the Ang II group were weaker than the control (P < 0.01). However, the mRNA and protein expression of P21 and P27 were significantly increased by the Eucommia lignans (20, 40, and 80 mg/L) (Figure 1).

3.3. Effects of Eucommia Lignans on Ang II-Induced Cellular Apoptosis in RMCs. The apoptotic rates in the Ang II group showed a slight increase compared with the control group (Figure 2). Furthermore, the apoptotic rates in the Eucommia lignans groups (20, 40, and 80 mg/L) were further increased compared with the Ang II group.

3.4. Effects of Eucommia Lignans on Ang II-Induced Bax and Bcl-2 Expression in Rat Mesangial Cells. Bax mRNA and protein expression levels were stronger in the Ang II group (Figure 3). Moreover, Bax expression was increased in the Eucommia lignans groups compared with the Ang II group. In contrast, there was no significant difference in Bcl-2 mRNA and protein expression between the Eucommia lignans groups and the Ang II group (P > 0.5).

3.5. Effects of Eucommia Lignans on Ang II-Induced AR in RMCs. The mRNA, protein expression, and activity of AR were effectively enhanced by Ang II (Figure 4). Eucommia lignans suppressed Ang II-induced AR expression in RMCs.

4. Discussions

Mesangial cells are the targets of bioactive factors (i.e., a variety of immune complexes, cytokines, thrombin, and integrins). These factors have a variety of physiological functions,
such as the secretion of extracellular matrix, devouring, shrinkage, and maintaining normal substrate metabolism [4]. However, RMCs show significant proliferation, which is the core pathological aspect of a variety of kidney diseases. In our previous study, rat mesangial cells treated with Ang II showed significant cell proliferation compared with the control group \((P < 0.01)\) [2]; the *Eucommia* lignans effectively inhibited the proliferation of mesangial cells induced by Ang II. The *Eucommia* lignans were able to postpone glomerular sclerosis and prevent the deterioration of renal function [5]. The process of cell proliferation is an evolutionary process controlled by the cell cycle. A significant reduction in the ratio of cells in \(G_1\) phase and significant elevation in the ratio of cells in \(S\) phase indicate cells in a state of proliferation. *Eucommia* lignans significantly increased the ratio of cells in \(G_1\) phase and decreased the ratio of cells in \(S\) phase during
the inhibition of proliferation. Thus, we concluded that the Eucommia lignans inhibited cell proliferation by acting on the cell cycle.

Consequently, we studied the cell cycle by analyzing the expression levels of the P21 and P27 genes. P21 is a negative regulator of the cell cycle, and elevated P21 expression prevents cells from transitioning from G1 to S phase [6, 7]. P27 is a pivotal negative regulatory protein in G1, and its expression level critically influences renal cell proliferation [8, 9]. Therefore, we measured the P21 and P27 mRNA and protein levels and found that P21 and P27 mRNA and protein expression in RMCs treated with Ang II was weaker, resulting in abnormal cell proliferation. The Eucommia lignans significantly increased the P21 and P27 mRNA and protein expression inhibited by Ang II. Thus, Eucommia lignans inhibited cell proliferation by acting on the cell cycle-related genes P21 and P27.

Maintaining the balance between cell proliferation and apoptosis is important for normal development and tissue homeostasis [10]. We assessed the apoptosis rates because apoptosis plays a critical role in the development of kidney disease [11]. The apoptosis rates in cells incubated with different concentrations of Eucommia lignans were higher compared to cells in the Ang II group. Based on these data, Eucommia lignans played an important role in promoting apoptosis.

Apoptosis is a complex process involving more than one gene [12]. Cell apoptosis plays a key role in renal disease outcome. Activated and proliferating RMCs can be eliminated through apoptosis, allowing the return of the normal structure and function of the glomerular [13]. Bcl-2 and Bax are two important genes involved in the apoptosis process. Bcl-2 is an antiapoptotic gene that belongs to a class of genes that inhibits apoptosis and can prevent the induction of apoptosis by a variety of factors. Indeed, excessive Bcl-2 expression can block the occurrence of apoptosis [14, 15]. Bax is a proapoptotic gene. Yamagishi et al. reported that apoptosis in diabetic nephropathy was related to Bax [16]. Our study showed that the Eucommia lignans significantly increased Bax expression and reduced the Bcl-2/Bax ratio. However, no obvious changes in Bcl-2 expression were observed in the present experiments. Based on these results, we speculated that the Ang II receptor type 2 activated phosphatase mitogen-activated protein kinase-1, resulting in the dephosphorylation of the Bcl-2 molecule and the loss of its antiapoptotic function [17]. Therefore, the change in Bax/Bcl-2 eventually resulted in apoptosis, and the Eucommia lignans promoted apoptosis by increasing Bax expression.

We also investigated apoptosis related to caspase-3 gene expression [18–20]; however, the results were not statistically significant.

AR, an important member of the aldehyde ketone reductase superfamily, is a rate-limiting enzyme in the polyol pathway involved in glucose metabolism [21]. AR is involved in the proliferation of mesangial cells, inflammation, apoptosis, tubular epithelial cell transition, and extracellular matrix deposition, which can induce hypertensive renal injury [22, 23]. Our previous study demonstrated that AR played an important role in the pathological processes of hypertension and hypertensive organ injury [2]. Therefore, we concluded that high expression of AR may have a causal relationship with renal injury. As shown in this study, AR expression was much higher in the Ang II group compared to the control group and was highest in the epalrestat group; in contrast, AR expression was significantly reduced in the groups treated with different concentrations of lignans compared to the Ang II group. One possible reason may be that AR was inhibited by epalrestat; when the level of activated AR was reduced sufficiently to impair the maintenance of the normal physiological functions of RMCs, the cells began to increase AR expression. However, the specific mechanism requires further research.

In conclusion, the results of this study indicated that Ang II induced the proliferation and apoptosis of RMCs by decreasing the expression of P21, P27, and Bax. Eucommia lignans may play a protective role in the kidneys by inhibiting proliferation and promoting apoptosis through the
upregulation of P21, P27, and Bax expression. The apoptosis related gene Bcl-2 showed no obvious effect in our study. This study provides convincing evidence for the use of *Eucommia* lignans in the therapy of kidney diseases.

5. Conclusions

*Eucommia* lignans are able to suppress the proliferation and promote the apoptosis of rat glomerular mesangial cells induced by Ang II by upregulating P21, P27, and Bax (but not Bcl-2) expression; AR may play a key role in this process.

Abbreviations

Ang II: Angiotensin II  
RMCs: Rat mesangial cells  
AR: Aldose reductase
Figure 4: Effect of lignans on AR in RMCs induced by Ang II. GAPDH was used as an internal loading control gene. All values were expressed as mean ± SD (n = 3). (a) Effect of lignans on activity of AR; (b) effect of lignans on mRNA expression of AR by RT-qPCR; (c1, c2) effect of lignans on protein expression of AR by western blot. Con: control; Ang II: 10⁻⁸ mol/L Ang II group; Epa: 10⁻⁸ mol/L Ang II + 20 μmol/L epalrestat group; L Lig: 10⁻⁸ mol/L Ang II + 20 mg/L lignan group; M Lig: 10⁻⁸ mol/L Ang II + 40 mg/L lignan group; H Lig: 10⁻⁸ mol/L Ang II + 80 mg/L lignan group; ∗P < 0.05, ∗∗P < 0.01 compared with the control group; #P < 0.05, ##P < 0.01, compared with the 10⁻⁸ mol/L Ang II group.

NCS: Newborn calf serum
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution
Dong-Sheng Ouyang, Hong-Hao Zhou, and Xian Jing designed this study. Xian Jing, Yong-Jun Tang, Ya-Qin Wang, Hui Li, Ying-Ying Tian, and Yao Chen performed the experiments. Xian Jing and Wei-Hua Huang wrote the paper. All authors have read and approved the final paper.

Acknowledgments
This study was supported by National Sci-Tech Support Plan of China (SQ2010BAY1411-08, to D.-S. Ouyang), National Development of Key Novel Drugs for Special Projects of China (2012ZX09303014001, to D.-S. Ouyang), Hunan Scientific Plan (14J4006, to D.-S. Ouyang), the National Scientific Foundation of China (no. 31400306, to W.-H. Huang), Hunan Provincial Natural Science Foundation of China (no. 2015JJ3156, to W.-H. Huang), and the Fundamental Research Funds for the Central Universities of Central South University (no. 1681-7608040003, to W.-H. Huang).

References
[1] E. Liu, L. Han, J. Wang et al., “Eucommia ulmoides bark protects against renal injury in cadmium-challenged rats,” Journal of Medicinal Food, vol. 15, no. 3, pp. 307–314, 2012.
[2] L. Li, J. Yan, K. Hu et al., “Protective effects of Eucommia lignans against hypertensive renal injury by inhibiting expression of aldose reductase,” Journal of Ethnopharmacology, vol. 139, no. 2, pp. 454–461, 2012.
[3] C. Rüster and G. Wolf, “Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1189–1199, 2011.
[4] Y. Xue, C.-R. Tie, J. Li, T. Tian, and Q.-X. Li, “Ligustrazine inhibits lipopolysaccharide-induced proliferation by affecting P27, Bcl-2 expression in rat mesangial cells,” European Journal of Pharmacology, vol. 665, no. 1-3, pp. 8–12, 2011.
[5] Z. Y. Li, X. L. Deng, W. H. Huang et al., "Lignans from the bark of *Eucommia ulmoides* inhibited Ang II-stimulated extracellular matrix biosynthesis in mesangial cells," *Chinese Medicine*, vol. 9, article 8, 2014.

[6] A. K. Khanna and J. D. Hosenpud, "In vitro and in vivo transfection of p21 gene enhances cyclosporin A-mediated inhibition of lymphocyte proliferation," *Journal of Immunology*, vol. 165, no. 4, pp. 1882–1888, 2000.

[7] O. Halevy, B. G. Novitch, D. B. Spicer et al., "Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD," *Science*, vol. 267, no. 5200, pp. 1018–1021, 1995.

[8] N. P. Malek, H. Sundberg, S. McGrew, K. Nakayama, T. R. Kyriakides, and J. M. Roberts, "A mouse knock-in model exposes sequential proteolytic pathways that regulate p27\(^{kip1}\) in G1 and S phase," *Nature*, vol. 413, no. 6853, pp. 323–327, 2001.

[9] N. P. Malek, H. Sundberg, S. McGrew, K. Nakayama, T. R. Kyriakides, and J. M. Roberts, "A mouse knock-in model exposes sequential proteolytic pathways that regulate p27\(^{kip1}\) in G1 and S phase," *Nature*, vol. 413, no. 6853, pp. 323–327, 2001.

[10] R. Simon, R. Aparicio, B. E. Housden, S. Bray, and A. Busturia, "Drosophila p53 controls Notch expression and balances apoptosis and proliferation," *Apoptosis*, vol. 19, no. 10, pp. 1430–1443, 2014.

[11] R. Bonegio and W. Lieberthal, "Role of apoptosis in the pathogenesis of acute renal failure," *Current Opinion in Nephrology and Hypertension*, vol. 11, no. 3, pp. 301–308, 2002.

[12] C. A. Heckman, J. W. Mehew, and L. M. Boxer, "NF-xb activates Bcl-2 expression in t(14;18) lymphoma cells," *Oncogene*, vol. 21, no. 24, pp. 3898–3908, 2002.

[13] H.-L. Li, D.-D. Chen, X.-H. Li et al., "Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species," *World Journal of Gastroenterology*, vol. 8, no. 3, pp. 431–435, 2002.

[14] S.-I. Yamagishi, Y. Inagaki, T. Okamoto et al., "Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells," *The Journal of Biological Chemistry*, vol. 277, no. 23, pp. 20309–20315, 2002.

[15] M. Horiiuchi, W. Hayashida, T. Kambe, T. Yamada, and V. J. Dzau, "Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis," *The Journal of Biological Chemistry*, vol. 272, no. 30, pp. 19022–19026, 1997.

[16] D. Boehm, C. Mazurier, M.-C. Giarratana et al., "Caspase-3 is involved in the signalling in erythroid differentiation by targeting late progenitors," *PLoS ONE*, vol. 8, no. 5, Article ID e62303, 2013.

[17] T. Matsumoto, K. Tabata, and T. Suzuki, "The GANT61, a GLI inhibitor, induces caspase-independent apoptosis of SK-N-LO cells," *Biological and Pharmaceutical Bulletin*, vol. 37, no. 4, pp. 633–641, 2014.

[18] G.-H. Wang, J. Xiang, R. Lan, X.-D. Zhen, W. Zhang, and D.-F. Cai, "An-Gong-Niu-Huang Wan protects against cerebral ischemia induced apoptosis in rats: up-regulation of Bcl-2 and down-regulation of Bax and Caspase-3," *Journal of Ethnopharmacology*, vol. 154, no. 1, pp. 156–162, 2014.

[19] J. Gu, J. J. Wang, J. Yan et al., "Effects of lignans extracted from *Eucommia ulmoides* and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling," *Journal of Ethnopharmacology*, vol. 133, no. 1, pp. 6–13, 2011.

[20] H. Masugata, S. Senda, M. Inukai et al., "Seasonal variation in estimated glomerular filtration rate based on serum creatinine levels in hypertensive patients," *The Tohoku Journal of Experimental Medicine*, vol. 224, no. 2, pp. 137–142, 2011.

[21] A. K. Bidani, K. A. Griffin, G. Williamson, X. Wang, and R. Loutzenhiser, "Protective importance of the myogenic response in the renal circulation," *Hypertension*, vol. 54, no. 2, pp. 393–398, 2009.